Japan has a high level of global competitiveness in life sciences fostered by sustained efforts and innovation breakthroughs that many researchers in academia, research institutions, and pharmaceutical companies are bringing forward. Our mission is to help such research outcomes to be funded and to catalyze the translation of innovative medicines serving the needs of the patients.
For patients suffering from diseases, for people
involved in healthcare such as researchers, medical doctors, and employees of
pharmaceutical companies, we contribute to the most promising technology
innovations through the hands-on leverage of our deep knowledge of the sector and
unique experiences in finance and drug development.
Fund: New Life Science I Investment Limited Partnership
Founded: February 7, 2019
Fund Size: JPY 10.1 billion yen (Final close at February 6, 2020)
GP: New Life Science I LLP
Stage: Company Creation, Seed, Early, Middle, Later
Company: Shinsei Capital Partners, Ltd.
Management: CEO Manabu Nakamura
Director Yoshiyuki Yamakawa (Chairman, HIBIKI Partners)
Director Nobuyuki Hata (Professor, Graduate Institute for Entrepreneurial Studies)
Director Takahisa Komoda (Senior Managing Executive Officer, SBI Shinsei Bank)
Auditor Fuyuki Kojima (Partner attorney, HIFUMI Law)
July 2004 Shinsei
Bank (current SBI Shinsei Bank) started Pre-IPO investment
in Private Equity division
Invested in 75 companies over 14 years from 2004 to 2018, and 27 listedFebruary 2019 Established Shinsei Capital Partners as a carve-out of Life Science
Investment Team in Shinsei Corporate Investment